Skip to main content
. 2011 Aug 3;6(8):e23317. doi: 10.1371/journal.pone.0023317

Figure 5. Treatment with rVP1 decreases NF-κB activation that modulates CCL2 production.

Figure 5

(A) Left panel: rVP1 inhibits NF-κB activation in an Akt-dependent manner. BNL cells transfected with empty vector, wild-type Akt (WT-AKT) or dominant active Akt (DA-AKT) were co-transfected with a NF-κB-luc reporter plasmid and a vector carrying the EGFP gene for 24 h. Cells were then treated with rVP1 diluted in medium containing 0.5% FBS for 6 h and lysed for NF-κB luciferase assay. The determined values of luciferase activity were normalized to EGFP expression. Each treatment was performed in triplicate, and data shown are representative of at least three independent experiments. Right panel: CCL2 production in BNL cells treated with InSolution™ NF-κB activation inhibitor (quinazoline derivative). The culture supernatants were assayed after incubation for 2 days. (B) Western blots of phospho-IKK. BNL cells were treated with 10 µg/ml LPS in the presence/absence of rVP1 for 30 min.